Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.47 -5.8%	$1.37	$1.05 ▼ $5.17	$159.17M	0.41	1.21 million shs	11.53 million shs
CDXC ChromaDex		$6.16	$2.41 ▼ $9.18	$611.50M	2.21	803,645 shs	554,788 shs
KALV KalVista Pharmaceuticals	$11.41 -0.8%	$12.47	$7.30 ▼ $15.50	$567.31M	-0.01	483,120 shs	1.08 million shs
XNCR Xencor	$8.14 -3.1%	$8.96	$7.16 ▼ $27.24	$579.32M	0.87	673,165 shs	1.62 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+1.38%	+1.38%	-3.92%	+33.64%
CDXC ChromaDex	0.00%	0.00%	0.00%	0.00%	+188.10%
KALV KalVista Pharmaceuticals	0.00%	-6.09%	-2.98%	-1.13%	-3.14%
XNCR Xencor	0.00%	-4.68%	+5.71%	-23.50%	-57.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4786 of 5 stars	3.6	2.0	0.0	2.4	1.7	0.6
CDXC ChromaDex	3.1625 of 5 stars	3.5	0.0	4.0	0.0	0.0	1.9
KALV KalVista Pharmaceuticals	4.2181 of 5 stars	3.6	1.0	4.4	3.1	2.5	0.6
XNCR Xencor	4.1701 of 5 stars	3.4	2.0	3.9	3.3	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	560.84% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	117.65% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	243.98% Upside

Current Analyst Ratings Breakdown

Latest ACRS, CDXC, XNCR, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	8.95	N/A	N/A	$1.44 per share	1.02
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
XNCR Xencor	$110.49M	5.24	N/A	N/A	$9.63 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest ACRS, CDXC, XNCR, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
CDXC ChromaDex	N/A	2.95	2.35
KALV KalVista Pharmaceuticals	N/A	10.44	10.44
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CDXC ChromaDex	15.41%
KALV KalVista Pharmaceuticals	N/A
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
CDXC ChromaDex	9.64%
KALV KalVista Pharmaceuticals	10.50%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable
XNCR Xencor	280	71.17 million	67.45 million	Optionable

ACRS, CDXC, XNCR, and KALV Headlines

Recent News About These Companies

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29 at 1:09 PM | ca.finance.yahoo.com

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling

June 17, 2025 | marketbeat.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 16, 2025 | marketbeat.com

Kurt A. Gustafson Sells 2,993 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Ellen Feigal Sells 2,993 Shares

June 16, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10, 2025 | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)

June 3, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

Xencor participates in a conference call with JPMorgan

April 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, CDXC, XNCR, and KALV Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.47 -0.09 (-5.77%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.58 +0.11 (+7.14%)

As of 05:30 AM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

KalVista Pharmaceuticals NASDAQ:KALV

$11.41 -0.09 (-0.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.70 +0.29 (+2.50%)

As of 05:30 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Xencor NASDAQ:XNCR

$8.14 -0.26 (-3.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.40 +0.26 (+3.19%)

As of 04:00 AM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time